Want to see AIDX full AI Analyst Report?
20/20 Biolabs, Inc. (AIDX) Ratios
20/20 Biolabs, Inc. Ratios
AIDX's free cash flow for Q2 2026 was $-600.11K. For the 2026 fiscal year, AIDX's free cash flow was increased by $5.35K and operating cash flow was $-605.46K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.60 | 1.50 | 4.25 | 5.97 | 3.52 |
| Quick Ratio | -46.59 | 1.47 | 4.19 | 5.92 | 3.41 |
| Cash Ratio | 416.54 | 1.32 | 4.04 | 5.40 | 1.49 |
| Solvency Ratio | -0.88 | -2.61 | -2.99 | 0.87 | 0.65 |
| Operating Cash Flow Ratio | -779.38 | -1.92 | -4.58 | 3.56 | -0.48 |
| Short-Term Operating Cash Flow Coverage | -10.91 | -15.68 | -28.26 | 29.03 | -7.41 |
| Net Current Asset Value | $ -2.69M | $ -44.70K | $ 2.22M | $ 6.89M | $ 4.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 310.35 | 0.42 | 0.33 | 0.20 | 0.23 |
| Debt-to-Equity Ratio | -66789.49 | 0.99 | 0.48 | 0.26 | 0.34 |
| Debt-to-Capital Ratio | 1.00 | 0.50 | 0.33 | 0.20 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 1.03 | 0.31 | 0.20 | 0.11 | 0.14 |
| Financial Leverage Ratio | -215.21 | 2.36 | 1.49 | 1.30 | 1.49 |
| Debt Service Coverage Ratio | -0.02 | -30.98 | -32.31 | 9.13 | 13.08 |
| Interest Coverage Ratio | -21.32 | -447.66 | -227.89 | 107.04 | 150.20 |
| Debt to Market Cap | 1.18 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest Debt Per Share | 205.25 | 0.32 | 0.44 | 0.51 | 0.50 |
| Net Debt to EBITDA | -73.63 | 0.05 | 0.33 | -3.25 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 29.56% | 20.56% | 7.66% | 46.31% | 48.79% |
| EBIT Margin | -175.18% | -323.06% | -446.64% | 15.18% | 20.18% |
| EBITDA Margin | -171.36% | -315.31% | -434.89% | 17.79% | 21.47% |
| Operating Profit Margin | -162.87% | -323.06% | -446.64% | 15.18% | 20.18% |
| Pretax Profit Margin | -182.82% | -316.81% | -448.73% | 19.77% | 21.53% |
| Net Profit Margin | -182.82% | -316.81% | -448.73% | 19.77% | 21.53% |
| Continuous Operations Profit Margin | -182.82% | -316.81% | -448.73% | 19.77% | 21.53% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 112.25% | 98.07% | 100.47% | 130.26% | 106.68% |
| Return on Assets (ROA) | -90.37% | -153.65% | -100.37% | 17.90% | 20.17% |
| Return on Equity (ROE) | 19447.70% | -361.86% | -149.07% | 23.33% | 30.07% |
| Return on Capital Employed (ROCE) | -198.95% | -250.70% | -118.77% | 15.86% | 24.22% |
| Return on Invested Capital (ROIC) | -1.87% | -233.56% | -115.24% | 15.57% | 23.79% |
| Return on Tangible Assets | 1.89% | -178.28% | -109.42% | 19.04% | 21.38% |
| Earnings Yield | -2.51% | -4.85% | -5.62% | 1.92% | 1.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 12.95 | 20.69 | 14.46 | 2.28 |
| Payables Turnover | 0.00 | 3.74 | 3.65 | 12.79 | 5.91 |
| Inventory Turnover | 0.01 | 29.51 | 21.68 | 68.19 | 19.98 |
| Fixed Asset Turnover | 0.00 | 1.97 | 1.21 | 6.62 | 5.73 |
| Asset Turnover | 0.49 | 0.48 | 0.22 | 0.91 | 0.94 |
| Working Capital Turnover Ratio | -13.07 | 0.88 | 0.25 | 1.60 | 2.33 |
| Cash Conversion Cycle | -154929.60 | -57.08 | -65.51 | 2.06 | 116.38 |
| Days of Sales Outstanding | 35686.29 | 28.18 | 17.64 | 25.25 | 159.90 |
| Days of Inventory Outstanding | 29445.68 | 12.37 | 16.84 | 5.35 | 18.27 |
| Days of Payables Outstanding | 220061.56 | 97.62 | 99.99 | 28.54 | 61.80 |
| Operating Cycle | 65131.97 | 40.54 | 34.48 | 30.60 | 178.17 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -306.83 | -0.54 | -0.97 | 1.22 | -0.23 |
| Free Cash Flow Per Share | -306.83 | -0.54 | -0.97 | 1.16 | -0.28 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -519757.00 | -493.32 | 22.17 | -4.71 |
| Capital Expenditure Coverage Ratio | 0.00 | -519757.00 | -493.32 | 22.17 | -4.71 |
| Operating Cash Flow Coverage Ratio | -1.50 | -1.72 | -2.23 | 2.40 | -0.46 |
| Operating Cash Flow to Sales Ratio | -938.68 | -1.48 | -3.25 | 0.52 | -0.11 |
| Free Cash Flow Yield | -1286.50% | -2.27% | -4.08% | 4.88% | -1.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -39.75 | -20.56 | -17.80 | 51.95 | 54.44 |
| Price-to-Sales (P/S) Ratio | 72.96 | 65.34 | 79.85 | 10.27 | 11.72 |
| Price-to-Book (P/B) Ratio | -7761.78 | 74.63 | 26.53 | 12.12 | 16.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.08 | -44.06 | -24.52 | 20.50 | -86.62 |
| Price-to-Operating Cash Flow Ratio | -0.08 | -44.06 | -24.57 | 19.58 | -105.02 |
| Price-to-Earnings Growth (PEG) Ratio | 0.82 | 1.53 | 0.05 | 11.43 | -0.27 |
| Enterprise Value Multiple | -116.21 | -20.67 | -18.04 | 54.49 | 54.12 |
| Enterprise Value | 407.26M | 114.22M | 111.72M | 107.22M | 111.80M |
| EV to EBITDA | -116.21 | -20.67 | -18.04 | 54.49 | 54.12 |
| EV to Sales | 199.14 | 65.18 | 78.44 | 9.69 | 11.62 |
| EV to Free Cash Flow | -0.21 | -43.95 | -24.09 | 19.35 | -85.86 |
| EV to Operating Cash Flow | -0.21 | -43.95 | -24.14 | 18.48 | -104.09 |
| Tangible Book Value Per Share | -32.33 | 0.22 | 0.79 | 1.82 | 1.33 |
| Shareholders’ Equity Per Share | -0.00 | 0.32 | 0.90 | 1.97 | 1.46 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.33 | 0.37 | 0.30 | 2.32 | 2.03 |
| Net Income Per Share | -0.60 | -1.16 | -1.34 | 0.46 | 0.44 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 0.98 | 1.00 | 1.30 | 1.07 |
| Research & Development to Revenue | 0.29 | 0.72 | 0.99 | 0.01 | 0.02 |
| SG&A to Revenue | 1.63 | 2.72 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.51 | 0.47 | 0.72 | 2.65 | -0.52 |
Currency in USD
